Current Challenges and Solutions for Clinical Management and Care of People with HIV: Findings from the 12th Annual International HIV and Aging Workshop
- PMID: 36322713
- PMCID: PMC9889016
- DOI: 10.1089/AID.2022.0079
Current Challenges and Solutions for Clinical Management and Care of People with HIV: Findings from the 12th Annual International HIV and Aging Workshop
Abstract
People with HIV on combination antiretroviral therapy (ART) have longer life expectancy and are increasingly experiencing age-related comorbidities. Thus, aging with HIV has become a central issue in clinical care and research, which has been particularly challenging with the intersection of the ongoing coronavirus (COVID)-19 pandemic. Since 2009, the International Workshop on HIV and Aging has served as a multidisciplinary platform to share research findings from cross-disciplinary fields along with community advocates to address critical issues in HIV and aging. In this article, we summarize the key oral presentations from the 12th Annual International Workshop on HIV and Aging, held virtually on September 23rd and 24th, 2021. The topics ranged from basic science research on biological mechanisms of aging to quality of life and delivery of care under the COVID-19 pandemic. This workshop enriched our understanding of HIV and aging under the COVID-19 pandemic, identified challenges and opportunities to combat the impact of COVID-19 on HIV communities, and also provided updated research and future directions of the field to move HIV and aging research forward, with the ultimate goal of successful aging for older people with HIV.
Keywords: COVID-19; HIV; aging; biological mechanism; delivery of care; quality of life.
Conflict of interest statement
D.J.B. is a co-inventor on patent applications licensed to or filed by Unity Biotechnology, a company developing senolytic strategies for treatment of age-related disorders, including small molecules that selectively eliminate senescent cells. Research in the Baker laboratory has been reviewed by the Mayo Clinic Conflict of Interest Review Board and is being conducted in compliance with Mayo Clinic Conflict of Interest policies. G.A.K. has served as consultant for Spring Discovery, resTORbio, and Janssen Pharmaceuticals. K.M.K. reports personal fees from Nuvaira (Data Safety and Monitoring Board co-chair) and Allergan (consulting).
G.G. received research grant and speaker honorarium from Gilead, ViiV, MERCK, and Jansen. G.G. attended advisory boards of Gilead, ViiV, and MERCK. A.W. has received speaker honoraria or grants to Imperial College London on behalf of Gilead Sciences, ViiV Health care, Janssen, and MSD. K.M.E. reports research funding from Gilead Sciences, and consulting payments from Gilead Sciences, Janssen Pharmaceuticals, and ViiV Pharmaceuticals (all paid to the University of Colorado).
References
-
- Centers for Disease Control and Prevention. HIV Surveillance Report, 2019; vol. 32. Published May 2021. Available from: https://www.cdc.gov/hiv/library/reports/hiv-surveillance.html [Last accessed: November 2, 2021].
Publication types
MeSH terms
Grants and funding
- T32 DA031098/DA/NIDA NIH HHS/United States
- P30 AI036214/AI/NIAID NIH HHS/United States
- K12 HD052023/HD/NICHD NIH HHS/United States
- P30 AG059988/AG/NIA NIH HHS/United States
- U01 AI165452/AI/NIAID NIH HHS/United States
- R25 AG073119/AG/NIA NIH HHS/United States
- R33 AG061456/AG/NIA NIH HHS/United States
- R25 MH108389/MH/NIMH NIH HHS/United States
- R01 AG068076/AG/NIA NIH HHS/United States
- R56 AG060746/AG/NIA NIH HHS/United States
- U54 AG075941/AG/NIA NIH HHS/United States
- R01 MH125720/MH/NIMH NIH HHS/United States
- R01 AG053229/AG/NIA NIH HHS/United States
- UM1 AI069432/AI/NIAID NIH HHS/United States
- T32 AI007384/AI/NIAID NIH HHS/United States
- U01 HL146201/HL/NHLBI NIH HHS/United States
- R01 CA242023/CA/NCI NIH HHS/United States
- P30 MH062512/MH/NIMH NIH HHS/United States
